Navigation Links
Tigris Pharmaceuticals, Inc. Completes $6.5 Million Private Placement
Date:9/28/2010

induce apoptosis by down-regulating several pivotal oncogenic and tumor survival pathways.

"We are extremely pleased to have completed this financing round, which will enable Tigris to proceed with the development of our two most advanced clinical compounds," stated Edmundo Muniz, MD, PhD, Tigris' President and Chief Executive Officer, adding, "we are honored to have the support of a group of high quality investors, who have demonstrated confidence in our clinical prospects and our management team."

"I am very excited about the opportunity to invest in and lead this financing round for Tigris Pharmaceuticals," said Mr. Flanzraich. "The combination of Tigris' pipeline potential, proven leadership performance, and its vision for the future holds great promise for patients and investors."

The securities were offered to accredited investors in reliance on an exemption from the registration requirements of the Securities Act of 1993 (the "Securities Act").  The offering has not been registered under the Securities Act or any state securities or "blue sky" laws and the shares may not be offered or sold absent registration or an applicable exemption from the registration requirements of the Securities Act and applicable state securities laws.

About Tigris Pharmaceuticals, Inc

Tigris Pharmaceuticals, Inc. is a privately held biopharmaceutical company that develops therapeutic technologies to treat oncology and other human diseases.  Tigris is currently initiating a Phase II trial for AFP-464, a novel anticancer agent in patients with breast cancer and is also conducting a multi-center Phase I dose escalation study for GGTI-2418, another first-in-class agent, at Abramson Cancer Center at The University of Pennsylvania and Indiana University Melvin and Bren Simon Cancer Center.  

With a management team that has a proven track record in guiding molecules from the early stages of clinical development to successful
'/>"/>

SOURCE Tigris Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Tigris Pharmaceuticals Initiates Phase I Study of AFP-464 in Patients with Solid Tumors
2. Tigris Pharmaceuticals Signs CRADA with the National Cancer Institute
3. Tigris Pharmaceuticals Appoints Neil Flanzraich to Executive Chairman of the Board
4. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
5. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
8. Sucampo Pharmaceuticals, Inc. Begins Pivotal Phase III Studies of Oral Lubiprostone to Treat Opioid-Induced Bowel Dysfunction (OBD)
9. Symbollon Pharmaceuticals, Inc. Evaluates the Clinical Effects of IoGen(TM) on Fibrocystic Breast Disease
10. Aegerion Pharmaceuticals, Inc. Presents Final Results of Phase II Clinical Trials for AEGR-733 at Drugs Affecting Lipid Metabolism (DALM) 2007 Conference
11. Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... 27, 2014  AcelRx Pharmaceuticals, Inc. (Nasdaq: ... development and commercialization of innovative therapies for the treatment ... management will be participating at the FBR Healthcare One ... Global Healthcare Conference.  Details of the two events are ... Conference Date: Wednesday September 3 rd Location: ...
(Date:8/26/2014)...  Kewaunee Scientific Corporation (Nasdaq: KEQU ) ... 31, 2014. Sales for the quarter were ... first quarter last year. Net earnings for the quarter ... to net earnings of $1,587,000, or $0.61 per diluted ... However, both sales and earnings in the first quarter ...
(Date:8/26/2014)... , Aug. 26, 2014  Actavis plc (NYSE: ... that Brenton Saunders , CEO and President of Actavis, ... at the Morgan Stanley Global Healthcare Conference 2014 in ... http://photos.prnewswire.com/prnh/20130124/NY47381LOGO The presentation will take place ... at the Grand Hyatt New York, 109 East 42 nd ...
Breaking Medicine Technology:AcelRx Pharmaceuticals to Participate in Two Upcoming Investor Events 2AcelRx Pharmaceuticals to Participate in Two Upcoming Investor Events 3Kewaunee Scientific Reports Results for First Quarter 2Kewaunee Scientific Reports Results for First Quarter 3Kewaunee Scientific Reports Results for First Quarter 4Kewaunee Scientific Reports Results for First Quarter 5Kewaunee Scientific Reports Results for First Quarter 6Actavis to Present at Morgan Stanley Global Healthcare Conference 2014 2
... , POTOMAC, Md., Nov. 24 In ... has added Philadelphia jurors to her Thanksgiving gratitude list. ... I am so thankful to them," she said of Monday,s ... , Wisneski is among 12,000 women nationwide who have sued ...
... , , HOLMDEL, ... TrackWise software and the market leader in enterprise quality and ... expanding consumer product company and the parent company for globally ... with TrackWise Enterprise Quality Management System (EQMS). The company is ...
Cached Medicine Technology:Maryland Woman Thankful for Wyeth Verdicts 2SSL International plc Embraces TrackWise(R) Software for Global Quality and Compliance Efforts 2SSL International plc Embraces TrackWise(R) Software for Global Quality and Compliance Efforts 3
(Date:8/27/2014)... 2014 (HealthDay News) -- A new genetic discovery about ... the bowel disorder, researchers report. The scientists ... how their genes work, and said these changes can ... the possibility of a simple diagnostic test for Crohn,s, ... develops and suggest possible gene targets for new treatments, ...
(Date:8/27/2014)... August, 27, 2014) An experimental drug designed to help ... first treatment for anemia of inflammation, according to results from ... online today in Blood , the Journal ... is a condition that occurs when red blood cells are ... individual has anemia, the body does not get enough oxygen, ...
(Date:8/27/2014)... tested an advanced statistical model to evaluate the ... as published yesterday in Human Genetics . ... in current analyses. Complex diseases like cancer usually ... factors. When many such combinations are studied, identifying ... combinations among affected individuals becomes difficult. In this ...
(Date:8/27/2014)... 2014 The Global and China Maleic ... the current state of the Maleic Anhydride industry in ... overview of the industry, including definitions, applications and industry ... analysis are provided with a focus on history, developments, ... between the international and Chinese situation is also offered. ...
(Date:8/27/2014)... Sugar Manufacturing in Australia ... in global supply and demand, which have contributed to ... industry derives a large share of its revenue from ... dynamics, with supply and prices being determined by larger ... Australian dollar for the majority of the past five ...
Breaking Medicine News(10 mins):Health News:Scientists Spot Genetic Clues to Crohn's Disease 2Health News:Drug represents first potential treatment for common anemia 2Health News:Dartmouth isolates environmental influences in genome-wide association studies 2Health News:Maleic Anhydride Industry & Isoprene Market Global and China Analysis Now Available at ReportsnReports.com 2Health News:Maleic Anhydride Industry & Isoprene Market Global and China Analysis Now Available at ReportsnReports.com 3Health News:Maleic Anhydride Industry & Isoprene Market Global and China Analysis Now Available at ReportsnReports.com 4Health News:Maleic Anhydride Industry & Isoprene Market Global and China Analysis Now Available at ReportsnReports.com 5Health News:Sugar Manufacturing in Australia Industry Market Research Report Now Updated by IBISWorld 2Health News:Sugar Manufacturing in Australia Industry Market Research Report Now Updated by IBISWorld 3Health News:Sugar Manufacturing in Australia Industry Market Research Report Now Updated by IBISWorld 4
... the Staying Sharp session on October 4 at the Embassy ... Part of a highly recognized series, the program will emphasize ... industry; factors that predict future cognitive function; and the importance ... The public can reserve free tickets through the toll-free line: ...
... articulating wall mounted arms that offer a space-saving solution without ... environment. , ... Ferndale, MI (PRWEB) ... the next generation in articulating wall-mounted arms. Offering 270 degrees ...
... Oct. 1 Sysmex America, Inc. and its,subsidiary, ... the,company,s new brand logo, said Kazuya Obe, Executive ... The timing of this brand change,corresponds with the ... and,the company,s 40th anniversary. The new logo marks ...
... with,solutions and recommendations drawing on experience working ... PLYMOUTH MEETING, Pa., Oct. 1 Anticipating,the ... Safety and Quality,Improvement Act of 2005, ECRI ... to improve patient care, will preview its ...
... Researchers at the Farber Institute for Neurosciences ... Psychiatry and Human Behavior at Jefferson Medical College ... $3.7 million grant from The National Eye Institute ... macular degeneration (AMD). Barry W. Rovner, M.D., ...
... Rise of cities, risky behavior in west central Africa between ... 1 (HealthDay News) -- The most pervasive global strain of ... a new study claims. , The research, which is ... that HIV began spreading between 1884 and 1924, around the ...
Cached Medicine News:Health News:Enovate IT Announces Fluid - a New Movement in Wall Arms 2Health News:Sysmex Announces Brand Change 2Health News:ECRI Institute Unveils Comprehensive Patient Safety Organization (PSO) Services 2Health News:ECRI Institute Unveils Comprehensive Patient Safety Organization (PSO) Services 3Health News:Jefferson awarded multi-million dollar grant from National Eye Institute for new clinical trial 2Health News:HIV Outbreak Began Decades Earlier Than Thought 2
TSH EIA Thyroid Function 025-BC-1001...
... The anti-TG test kit is a ... microplate format. It is designed for the ... thyroglobulin (TG) in serum or plasma. The ... 1: Calibrators, controls and patient samples are ...
Free Estriol (E3) RIA Reproductive Hormones 024-IDC-1000...
FSH EIA Reproductive Markers 025-BC-1029 Follicle Stimulating Hormone...
Medicine Products: